A subsidiary of Canadian pharmaceutical company Draxis Health of Mississauga, Ontario, has begun phase I clinical trials of Fibrimage, a peptide-based agent for the detection of deep vein thrombosis (DVT). If it reaches the market, Fibrimage could be a
A subsidiary of Canadian pharmaceutical company Draxis Health of Mississauga, Ontario, has begun phase I clinical trials of Fibrimage, a peptide-based agent for the detection of deep vein thrombosis (DVT). If it reaches the market, Fibrimage could be a competitor to Diatide's AcuTect peptide-based radiopharmaceutical, which is also targeted at DVT.
Draxis acquired rights to Fibrimage through its purchase of the radiopharmaceutical business of Merck Frosst Canada, which licensed the polypeptide that forms the basis of the agent from Bio-Technology General of Iselin, NJ. Draxis renamed the Merck Frosst Canada unit Draximage and made it one of four Draxis business units.
In addition to developing Fibrimage, Draximage sells radiopharmaceuticals in ready-to-use forms for the treatment and diagnosis of thyroid gland disorders and kidney and lung function. It also sells freeze-dried non-radioactive kits for the diagnosis of inflammatory and neoplastic bone disease and kidney and lung ventilation studies.
Fibrimage is based on fibrin binding domain (FBD), a recombinant polypeptide with a high binding affinity for fibrin, the primary component of a venous thrombus. FBD, which was developed by Bio-Technology General, is a lyophilized (freeze-dried) kit that is labeled with technetium-99m prior to use with a labeling process that was developed by the Merck Frosst Canada unit before its acquisition by Draxis.
The phase I study of Fibrimage should be completed by the fourth quarter, with a phase II study to begin shortly thereafter. Draximage believes the technology could be an alternative to contrast venography and Doppler ultrasound for the detection of DVT.
MRI-Based AI Radiomics Model Offers 'Robust' Prediction of Perineural Invasion in Prostate Cancer
July 26th 2024A model that combines MRI-based deep learning radiomics and clinical factors demonstrated an 84.8 percent ROC AUC and a 92.6 percent precision-recall AUC for predicting perineural invasion in prostate cancer cases.
Breast MRI Study Examines Common Factors with False Negatives and False Positives
July 24th 2024The absence of ipsilateral breast hypervascularity is three times more likely to be associated with false-negative findings on breast MRI and non-mass enhancement lesions have a 4.5-fold likelihood of being linked to false-positive results, according to new research.
Can Polyenergetic Reconstruction Help Resolve Streak Artifacts in Photon Counting CT?
July 22nd 2024New research looking at photon-counting computed tomography (PCCT) demonstrated significantly reduced variation and tracheal air density attenuation with polyenergetic reconstruction in contrast to monoenergetic reconstruction on chest CT.